Lonza Group (OTCMKTS:LZAGY) Stock Rating Upgraded by Royal Bank Of Canada

Lonza Group (OTCMKTS:LZAGY) was upgraded by equities research analysts at Royal Bank Of Canada from a “hold” rating to a “moderate buy” rating in a research note issued on Wednesday,Zacks.com reports.

Separately, Zacks Research downgraded Lonza Group from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Lonza Group currently has an average rating of “Hold”.

Lonza Group Price Performance

Shares of LZAGY stock opened at $65.63 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.87 and a current ratio of 1.46. The company’s fifty day moving average price is $68.05 and its 200-day moving average price is $68.53. Lonza Group has a one year low of $55.57 and a one year high of $73.85.

About Lonza Group

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.